Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Use of cardiotrophin-1 for the treatment of kidney diseases

A cardiotrophin, CT-1 technology, applied in the direction of urinary system diseases, medical preparations containing active ingredients, cytokines/lymphokines/interferon, etc., can solve problems such as inability to prevent or treat kidney damage

Inactive Publication Date: 2014-06-11
DIGNA BIOTECH +1
View PDF11 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, administration of isolated IL-6 polypeptide, in the absence of its receptor, does not prevent or treat kidney injury

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of cardiotrophin-1 for the treatment of kidney diseases
  • Use of cardiotrophin-1 for the treatment of kidney diseases
  • Use of cardiotrophin-1 for the treatment of kidney diseases

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment

[0227] A. Effect of blocking CT-1 with anti-CT-1 antibody

[0228] Materials and Methods

[0229] Reagents and Chemicals

[0230] Mouse anti-cardiotrophin-1 antibody and preimmune goat IgG control were provided by Digna-Biotech (Pamplona, ​​Spain) and prepared by R&D Systems (Minneapolis, MN). Both agents were dissolved in 0.9% saline solution to a final concentration of 5 μg / ml. For anesthesia, a 2:2:1 mixture of ketamine (Ketolar, Pfizer), benzodiazepine (Valium, Roche), and atropine (Atropina, Braun) was used. For the postoperative period, buprenorphine 0.3 mg / ml (Buprex, Schering-Plough) was purchased.

[0231] animal

[0232] Male wild-type C57BL / 6 mice (Charles River Laboratories S.L., UK) were housed under standard animal care conditions and provided with standard mouse chow and water with free access before and after surgery. Induction of I / R injury was performed using the previously described protocol (Docherty, N.G. et al. 2006. Nephrol. Dial. Transplant. (8):21...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of cardiotrophin-1 (CT-1) for the prevention and / or treatment of acute renal injury, specially of acute kidney injury induced by nephrotoxic agents, such as contrast agents, antibiotics, immunosuppressive agents or antineoplastic agents. The invention is also related to compositions comprising said nephrotoxic agents and cardiotrophin-1.

Description

technical field [0001] The present invention relates to the use of cardiotrophin-1 (CT-1) for preventing and / or treating acute kidney injury, especially acute kidney injury induced by nephrotoxic agents. Likewise, the present invention also relates to compositions comprising said nephrotoxic agent and cardiotrophin-1. Background technique [0002] Acute kidney injury (AKI) is a complex process of damage to various kidney structures that leads to a sudden loss of all or part of renal function, producing acute renal failure (AKF) within a short period of time, ranging from hours to days (López -Novoa JM. Kidney Int. 1999;55:1672-1682; López-Novoa JM et al. Kidney Int. 2011;79:33-45). Typically, the term AKI is used to define the reversible nature of most renal insults; whereas the term AKF is reserved to describe conditions in patients with renal impairment that include decreased glomerular filtrate and renal excretion for which renal replacement therapy is required ( KRT), ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/19A61P39/02A61K33/243
CPCA61K31/7036A61K38/22A61K38/19A61K33/24C07K14/52A61P13/12A61P39/02A61P43/00A61K33/243
Inventor 贝戈尼亚·加西亚·塞纳多哈维尔·加西亚·克里亚弗朗西斯科·哈维尔·洛佩斯·埃尔南德斯何塞·米格尔·洛佩斯·诺沃亚玛丽亚·皮拉尔·佩雷斯德·奥瓦诺斯·马特利胡安·鲁伊斯·埃切维里亚
Owner DIGNA BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com